1 / 35

AML Research Focus: Exploring New Treatment Options

Dive into off-label and investigational AML treatments with preliminary data on genetic mutations, current paradigms, and promising agents. Stay informed on the latest research to navigate AML care effectively.

yeo-clayton
Download Presentation

AML Research Focus: Exploring New Treatment Options

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AML Research Focus: Exploring New Treatment Options

  2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

  3. AML Basic Facts

  4. Trends in OS

  5. Genetic Mutations in AMLFunctional Categories

  6. Mutational Profile of AMLPatients Aged < 60 Years

  7. Treating Newly Diagnosed AMLCurrent Paradigms

  8. CPX-351 vs 7+3Older ND High-Risk (Secondary) AML, Phase 3

  9. CPX-351 vs 7+3Phase 3 Study Results

  10. Small Molecule Inhibitors

  11. FLT3 Mutations in AML

  12. Chemotherapy +/- MidostaurinFLT3-Mutated ND AML

  13. Chemotherapy +/- MidostaurinCALGB 10603/RATIFY, Results

  14. Quizartinib FLT3-ITD+ R/R AML

  15. GilteritinibFLT3-Mutated R/R AML

  16. Crenolanib FLT3-Mutated R/R AML

  17. Crenolanib With 7+3 InductionND FLT3-Mutant AML

  18. IDH Mutations

  19. Enasidenib (AG-221)IDH2-Mutated AML, Phase 1/2

  20. Ivosidenib (AG-120)IDH1-Muated AML, Phase 1

  21. IDH305 IDH1R132 Mutated-AML, Phase 1

  22. Venetoclax + Hypomethylating Agents Treatment-Naive Older AML, Phase 1b

  23. Venetoclax Plus Low-Dose Cytarabine Treatment-Naive Older AML

  24. MDM2 InhibitorsDS-3032binHematologic Malignancies

  25. Vadastuximab Talirine (SGN-CD33A) + HMAsOlder Patients With Treatment-Naive AML

  26. Vadastuximab Talirine Plus 7+3 Induction Therapy for ND AML, Phase 1b

  27. Agents/Trials to WatchHypomethylating Agents

  28. Agents/Trials to Watch Inhibitors of Nuclear Export

  29. Agents/Trials to WatchImmunotherapy

  30. BEAT AML Master Trial

  31. Key Takeaways

  32. Abbreviations

  33. Abbreviations (cont)

  34. Abbreviations (cont)

  35. Abbreviations (cont)

More Related